Pharmacodynamic study of 131I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer

Abstract

Abstract. The aim of the present study was to explore the inhibitory effect of 131 I-labeled ovarian cancer antigen 215 ( 131 I-CA215) antibody on human OC-3-VGH ovarian cancer. A subcutaneous transplanted tumor model of estrogen-resistant human OC-3-VGH ovarian cancer in nude mice was established. The model mice were randomly divided into seven groups, which were the negative control (NC), positive control (PC; 60 mg/kg cyclophosphamide), high-dose CA215 antibody (HA; 10 mg/kg), low-dose CA215 antibody (LA; 2 mg/kg), high-dose IntroductionOvarian cancer seriously impedes the reproductive health of females. Data from the American Cancer Society show that ovarian cancer is the ninth most common type of cancer in females (excluding skin cancer). It ranks fifth as the cause of cancer mortality in females. In 2013, it was estimated that there were ~22,240 new cases of ovarian cancer and ~14,230 individuals succumbed to this cancer (1). In China, ovarian cancer is the third most frequent cause of mortality among females (2). However, due to factors including environmental factors and drug treatment, the cell types and subtypes of ovarian cancer are increasing. For example, the OC-3-VGH cell line is a line of ovarian cancer that seldom expresses the estrogen receptor (3), and is insensitive to estrogen. The OC-3-VGH cell line was first successfully isolated in Taiwan (3). However, few studies have been conducted on this tumor type. The successful establishment of an animal model of OC-3-VGH would provide a drug study platform for the treatment of patients with estrogen-resistant ovarian cancer.In radioimmunotherapy (RIT), a highly specific pro-tumor substance is used as a carrier. Based on the specificity of the carrier and its affinity for the tumor, radionuclides are released in a targeted manner to focus their lethal effect on tumor cells. This is a non-toxic treatment method for the host(4,5). RIT is becoming a focus of study internationally. However, studies on RIT of ovarian cancer are limited (6). In the present study, a xenograft model of human OC-3-VGH ovarian cancer in nude mice was established to investigate the in vivo tumor inhibitory effect of 131 I-labeled ovarian cancer antigen 215 ( 131 I-CA215) antibody. This may provide the basis of further drug studies and a theoretical basis for the use of radiation therapy in the treatment of patients with estrogen-resistant ovarian cancer. Materials and methods Materials

Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy

“…In general, T/C > 40% revealed little anti-tumor effect, while T/C ≤ 40% ( P < 0.05) represented a sound therapeutic effect. 26,27…”

Therapy of cervical cancer using 131I-labeled nanoparticles

“…The tumor inhibition rate (TIR) was calculated by comparing the weights of the transplanted tumors of the treatment group with those of the negative control group as follows: TIR (%) = (1-mean weight of the transplanted tumor of the treatment group per mean weight of the transplanted tumor of the negative control group) × 100. 21 The therapy groups were followed for 30 days after injection and then killed.…”